Harvard Bioscience (HBIO) Share-based Compensation (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Share-based Compensation data on file, last reported at $2.2 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 2833.33% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $2.2 million, a 192.32% increase from a year earlier, with the FY2025 full-year figure at $1.9 million, down 54.76% from the prior year.
• Share-based Compensation for Q1 2026 stood at $2.2 million, up from $459000.0 in the prior quarter.
• Over the last five years, Share-based Compensation for HBIO reached as high as $2.2 million in Q2 2025 and fell as low as -$3.4 million in Q4 2024.
• Historically, Share-based Compensation has averaged $572058.8 across 5 years, with a median of $704000.0 in 2023.
• Across the five-year window, Share-based Compensation sank 649.22% in 2024 and soared 2833.33% in 2026, its largest moves.
• Year by year, Share-based Compensation stood at $1.5 million in 2022, then plunged by 129.44% to -$451000.0 in 2023, then sank by 649.22% to -$3.4 million in 2024, then soared by 113.58% to $459000.0 in 2025, then surged by 379.3% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $2.2 million in Q1 2026, $459000.0 in Q4 2025, and $18000.0 in Q3 2025.